Drugdocs | Annovera

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Annovera

Chemical Name	segesterone acetate and ethinyl estradiol vaginal system
Dosage Form	Vaginal system (intravaginal; 0.15 mg/day of segesterone acetate, 0.013 mg/day of ethinyl estradiol)
Drug Class	Miscellaneous
System	Female reproductive
Company	TherapeuticsMD, Inc.
Approval Year	2018

Indication

To prevent pregnancy in females of reproductive potential.

Last updated on 10/14/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Annovera (Segesterone Acetate and Ethinyl Estradiol Vaginal System) Prescribing Information	2018	TherapeuticsMD, Inc., Boca Raton, FL

Document Title	Year	Source
Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.	2019	The Lancet